Company Description
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally.
The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure; Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6; Promacta/Revolade for immune thrombocytopenia (ITP), thrombocytopenia, and aplastic anemia patients; Tafinlar+Mekinist, an oral combination therapy to treat cancer patients; and Jakavi for treating myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease.
It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in chronic and/or accelerated phase; Xolair for treating allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Stills disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma to treat genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta.
The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology.
It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran) to reduce LDL cholesterol.
Novartis AG has a strategic alliance with CAS for enhancing reaction data accessibility and supporting AI-enabled research.
Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
| Country | Switzerland |
| Founded | 1895 |
| IPO Date | Nov 18, 1991 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 75,267 |
| CEO | Vasant Narasimhan |
Contact Details
Address: Lichtstrasse 35 Basel, 4056 Switzerland | |
| Phone | 41 61 324 11 11 |
| Website | novartis.com |
Stock Details
| Ticker Symbol | NVS |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001114448 |
| CUSIP Number | 66987V109 |
| ISIN Number | US66987V1098 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Vasant Narasimhan M.D. | Chief Executive Officer |
| Victor Bulto | President of US |
| Dr. Patrick Horber M.D. | President of International |
| Mukul Mehta | Chief Financial Officer |
| Dr. Steffen Lang Ph.D. | President of Operations |
| Paul Penepent | Head of Group Financial Reporting and Accounting |
| Sloan Simpson | Global Head of Investor Relations |
| Karen L. Hale | Chief Legal and Compliance Officer |
| Dr. Robert Kowalski Pharm.D. | Chief People and Organization Officer |
| Evan Beckman | Global Head of Translational Medicine at Novartis Institute for BioMedical Research |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 28, 2026 | 144 | Filing |
| Oct 27, 2026 | SCHEDULE 13G/A | Filing |
| Oct 27, 2026 | 6-K | Report of foreign issuer |
| Sep 8, 2026 | 6-K | Report of foreign issuer |
| Sep 4, 2026 | 6-K | Report of foreign issuer |
| Sep 1, 2026 | 6-K | Report of foreign issuer |
| Jul 21, 2026 | 6-K | Report of foreign issuer |
| Jun 11, 2026 | 6-K | Report of foreign issuer |
| Apr 30, 2026 | 144 | Filing |
| Apr 28, 2026 | 6-K | Report of foreign issuer |